RheumNow Live 2026

Description

+ Include: 43 Videos (.mp4) + 43 Subtitles (.vtt) + 29 PDFs, size: 27.63 GB

+ Target Audience: rheumatologists and immunologists

+ Sample video: contact me for sample video

+ Information:

1. Overview

RheumNow Live 2026 provides a comprehensive and cutting-edge clinical update on rheumatology and autoimmune diseases. The program features expert insights into the diagnosis, management, and emerging therapies for conditions such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and gout, along with specialized updates on vasculitis, osteoporosis, and osteoarthritis.

Course Date: February 7-8, 2026

2. Learning Objectives

• Evaluate recent advances in the diagnosis and management of rheumatoid arthritis, including interstitial lung disease (ILD) complications and the mucosal hypothesis.

• Implement updated treatment algorithms for axial spondyloarthritis, psoriatic arthritis (including IL-23 vs IL-17 inhibitors), and gout.

• Analyze the evolving treatment landscapes for systemic autoimmune conditions such as large and small vessel vasculitis and Sjögren’s syndrome.

• Assess the impact of patient comorbidities, including obesity and inflammation, and apply risk mitigation strategies for rheumatic patients undergoing orthopedic surgery.

• Identify emerging therapeutic options and mechanisms of action presented in clinical showcases for advanced rheumatic disease management.

3. Target Audience

Best for rheumatologists and immunologists who want updates on rheumatoid arthritis, spondyloarthritis, and emerging autoimmune therapies.

4. Topics

1. 2026 Advances in Spondyloarthritis

2. Advancing Practice Faculty QA

3. Asymptomatic Elevation of CK

4. Autoimmune Faculty QA

5. Closing Comments Adjourn

6. Diagnosing Axial Spondyloarthritis in 2026

7. Disease Modification in Osteoarthritis

8. Embracing Relapses in PMR and GCA

9. Helicobacter Pylori Update

10. Highlights in Autoimmune Disease

11. History of Gout

12. IL-23 vs IL-17 inhibitors in PsA

13. ILD in RA – Recent Advances

14. Large Small Vessel Vasculitis

15. Mitigating Risk for Rheumatic Disease Patients Undergoing Orthopedic Surgery

16. Mortality in Rheumatoid Arthritis A Story of Decline Delay or Plateau

17. Obesity and Inflammation Weight Management in Rheumatology

18. Osteoporosis A 50 Year Journey

19. Paradoxical Psoriasis and Strange Reactions

20. Past Present Future of Gout

21. Placebos in Rheumatology

22. Pod 1 Rheumatoid Arthritis Achieving Better Outcomes

23. POD 2 Advancing Practice

24. POD 3 Decisions in Psoriatic Arthritis

25. Post-Reception Performance

26. Psoriatic Arthritis Faculty QA

27. Rheumatoid Arthritis Faculty QA

28. Sjogrens Treatment Landscape in 2026

29. Small Vessel Vasculitis

30. SMILE Study – Hydroxychloroquine in ANA Arthralgia

31. Spondyloarthritis Complications

32. Spondyloarthritis Faculty QA

33. Staying Ahead of Spondyloarthritis

34. The Mucosal Hypothesis of Rheumatoid Arthritis

35. Update on Myositis Antibodies

36. Vasculitis Faculty QA

37. VIRTUAL SHOWCASE AMGEN

38. VIRTUAL SHOWCASE Eli Lilly

39. VIRTUAL SHOWCASE Genentech

40. VIRTUAL SHOWCASE Sanofi

41. Welcome Introduction 2

42. Welcome Introduction

43. Why Do Plain Xrays in Psoriatic Arthritis